The global Diabetes Drugs Market size was valued at USD 84.65 billion in 2024 and is expected to be worth around USD 177.74 ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth ... Instead, the beat came from insulin, thanks to favorable U.S. rebate adjustments, analysts said.

The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

Novo Nordisk is also pairing the long-acting insulin with its once-weekly GLP-1 agonist semaglutide in the COMBINE trials programme, which is due to complete in 2024, is also working on a glucose ...

With sales of Novo Nordisk’s obesity blockbuster Wegovy ... over the same stretch. Novo’s total insulin sales totaled 55.37 billion kroner ($7.7 billion) versus 48 billion kroner in 2023.

US regulators believe that Novo Nordisk’s new long-acting, once-a-day insulin, Tresiba, has a notable, but uncertain, cardiovascular risk. An initial assessment, based on a pooled analysis ...

Between 2012 and 2021, the price for a one-month supply of insulin increased nearly 200%, peaking at $541 per month in 2019, according to the Health Care Cost Institute. The three major brand-name ...

The settlement filed in Newark, N.J. federal court comes after similar settlements with Eli Lilly and Sanofi last year. It ...

In addition, the company has experience with negotiations since Novo Nordisk has already gone through a similar process with its insulin products. The U.S. government started negotiating prices ...